Literature DB >> 33587502

Brief Report: Herpes Simplex Virus Type-2 Shedding and Genital Ulcers During Early HIV in Zimbabwean Women.

Rebecca G Nowak1, Tobias A Liska2, Søren M Bentzen3, Esther Kim4, Tsungai Chipato5, Robert A Salata6, David D Celentano7, Charles S Morrison8, Patti E Gravitt3.   

Abstract

BACKGROUND: Herpes simplex virus type-2 (HSV-2) seropositive persons have a 3- to 5-fold higher risk of acquiring HIV, possibly because of HSV-2-induced inflammation and recruitment of susceptible immune cells to exposure sites. We hypothesized that cervical HSV-2 activation (ie, viral DNA shedding and/or ulcers) preceded HIV acquisition in the hormonal contraception and HIV cohort.
METHODS: Zimbabwean women who acquired HIV were matched to HIV-negative women on visit, age, and bacterial sexually transmitted infections. Up to 5 cervical swabs bracketing first polymerase chain reaction detection of HIV DNA (the index visit) were selected (t-6months, t-3months, tindex, t+3months, t+6months). Women with HSV-2 immunoglobulin G+ before tindex were polymerase chain reaction tested for viral shedding. Self-reported and clinician-diagnosed ulcers were documented. Multivariable logistic regression, accounting for matching, estimated adjusted odds ratios (aOR) and 95% confidence intervals (CIs) at each visit.
RESULTS: Of 387 HSV-2 seropositive women, most had prevalent as compared with incident HSV-2 (91% vs. 9%, respectively). HSV-2 viral shedding was more common among HIV seroconverters than HIV-negative women (26% vs. 14%, P < 0.01). Shedding occurred around HIV acquisition (t-3months aOR, 2.7; 95% CI, 0.8 to 8.8; tindex aOR, 2.6; 95% CI, 1.1 to 6.5; t+3months aOR, 2.6; 95% CI, 1.0 to 6.6). Genital ulcers were reported more often among HIV seroconverters than HIV-negative women (13% vs. 7%; P = 0.06) and detection was after HIV acquisition (t+6months aOR, 14.5; 95% CI, 1.6 to 133.9).
CONCLUSIONS: HSV-2 shedding appeared synergistic with HIV acquisition followed by presentation of ulcers. Evaluating all sexually transmitted infections rather than HSV-2 alone may clarify the relationship between inflammation and HIV acquisition.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33587502      PMCID: PMC8131209          DOI: 10.1097/QAI.0000000000002641

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  32 in total

1.  Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.

Authors:  Warren Phipps; Misty Saracino; Amalia Magaret; Stacy Selke; Mike Remington; Meei-Li Huang; Terri Warren; Corey Casper; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

2.  Hormonal contraception and the risk of HIV acquisition.

Authors:  Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

3.  Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe.

Authors:  Rebecca G Nowak; Patti E Gravitt; Charles S Morrison; Stephen J Gange; Cynthia Kwok; Amy E Oliver; Roslyn Howard; Barbara Van der Pol; Robert A Salata; Nancy S Padian; Tsungai Chipato; Marshall Munjoma; David D Celentano
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

4.  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Authors:  Christine Johnston; Misty Saracino; Steve Kuntz; Amalia Magaret; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; David M Koelle; Lawrence Corey; Anna Wald
Journal:  Lancet       Date:  2012-01-04       Impact factor: 79.321

5.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Authors:  Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 7.  Epidemiology of herpes simplex virus type 2 infection in the developing world.

Authors:  Helen Weiss
Journal:  Herpes       Date:  2004-04

8.  Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy.

Authors:  Christine M Posavad; Anna Wald; Steven Kuntz; Meei Li Huang; Stacy Selke; Elizabeth Krantz; Lawrence Corey
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226

Review 9.  Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Authors:  Christine Johnston; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

10.  Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.

Authors:  Deborah Watson-Jones; Helen A Weiss; Mary Rusizoka; John Changalucha; Kathy Baisley; Kokugonza Mugeye; Clare Tanton; David Ross; Dean Everett; Tim Clayton; Rebecca Balira; Louise Knight; Ian Hambleton; Jerome Le Goff; Laurent Belec; Richard Hayes
Journal:  N Engl J Med       Date:  2008-03-12       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.